Beam Therapeutics, Inc. (BEAM) Stock Price, Financials & Summary

Price chart

Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5

Key dataNov 5, 2026

Open$27.37

From 52W high−31.78%

Volume2.98M

Market cap$2.68B

P/E (TTM)—

P/S (TTM)18.3x

Div yield—

Key dataNov 5, 2026

Open

$27.37

From 52W high

−31.78%

Volume

2.98M

Market cap

$2.68B

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−22.1x

P/E (TTM)

—

RSI (14)

51.4

MomentumView details →

1D Return

−6.91%

YTD Return

−5.79%

SummaryUpdated Sep 1, 2026

Beam Therapeutics Inc. (NASDAQ:BEAM) is a biotechnology company founded in 2017 and based in Cambridge, Massachusetts. The company went public in February 2020 and has emerged as a leader in precision genetic medicine, specifically focusing on base editing technology to develop treatments for serious genetic diseases. Beam has built a comprehensive pipeline of experimental therapies targeting blood disorders, liver diseases, and other genetic conditions, with several programs advancing through clinical trials.

Ask drillr about Beam Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−22.1x

EV/Sales

12.8x

P/S (TTM)

18.3x

P/B (TTM)

2.8x

ProfitabilityView details →

Gross Margin

100.00%

Net Margin

−73.04%

EBITDA Margin

−57.95%

ROE (TTM)

−11.24%

ROA (TTM)

−8.44%

Asset Turnover

0.11x

GrowthView details →

Revenue YoY

+163.27%

EPS YoY

+77.43%

FCF YoY

−13.02%

Revenue CAGR 3Y

+31.88%

EPS CAGR 3Y

+82.31%

EBITDA YoY

+78.88%

MomentumView details →

1D Return

−6.91%

YTD Return

−5.79%

1Y Return

+12.81%

RSI (14)

51.4

vs 50D SMA

+1.75%

vs 200D SMA

−6.88%

Capital & dividendView details →

Debt/Equity

0.26x

Current Ratio

13.00x

Quick Ratio

13.00x

Div Yield

—

Div Rate

—

Div Growth 1Y

−75.00%

EarningsView details →

EPS (Actual)

−$1.28

EPS Surprise

−11.30%

Beats (12Q)

4/12

Next Q EPS Est

−$1.21

Avg Surprise (4Q)

17.24%

Rev Surprise

−96.49%

Financials snapshotView financials →

Revenue (TTM)

146.64M

Net Income (TTM)

−107.10M

Op. CF (TTM)

−388.65M

Next earningsFeb 23, 2027 →

Latest newsMore news →

Beam Therapeutics Inc. reported updated BEAM-302 Phase 1/2 clinical data presented at ERS, showing durable increases in functional AAT and reductions in mutant Z-AAT.3d ago

Beam Therapeutics Inc. reported its third-quarter 2026 financial results.3d ago

Similar companies

Vericel CorporationVCEL Genor Biopharma Holdings Limited06998.HK 寿仙谷603896.SH Laekna, Inc.02105.HK Soleno Therapeutics, Inc.SLNO 凯因科技688687.SH Find similar companies →

Latest newsMore news →

Beam Therapeutics Inc. reported updated BEAM-302 Phase 1/2 clinical data presented at ERS, showing durable increases in functional AAT and reductions in mutant Z-AAT.3d ago Beam Therapeutics Inc. reported its third-quarter 2026 financial results.3d ago